 |
 |
 |
 |
 |
I realize that strategies for therapy and monitoring disease in HIV infection is
in a state of flux, but I have been asked to develop an algorithm for an HMO,
and I wonder if the NIH panel recommendations of a few years ago are still
timely. Are decision points for treatment and monitoring still focus on CD4
counts of 500/ul and 200/ul for anti-retroviral and PCP prophylaxis,
respectively? Any recent references would be appreciated.
Thanks,
D.A.Sadler, MD
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web